Capital Fund Management (CFM)’s Edwards Lifesciences EW Stock Holding History

Capital Fund Management (CFM)’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.64M	Buy	+20,500	New	+$1.69M	0.01%	1456
2025 Q4	–	Sell	-47,600	Closed	-$3.7M	–	2455
2025 Q3	$3.7M	Buy	47,600 +14,000	+42%	+$1.09M	0.01%	1420
2025 Q2	$2.63M	Buy	+33,600	New	+$2.51M	0.01%	1523
2025 Q1	–	Sell	-46,400	Closed	-$3.43M	–	2106
2024 Q4	$3.43M	Buy	46,400 +5,700	+14%	+$399K	0.01%	1266
2024 Q3	$2.69M	Buy	40,700 +21,100	+108%	+$1.53M	0.01%	1295
2024 Q2	$1.81M	Sell	19,600 -142,000	-88%	-$12.6M	0.01%	1425
2024 Q1	$15.4M	Sell	161,600 -70,800	-30%	-$5.95M	0.04%	545
2023 Q4	$17.7M	Buy	232,400 +93,400	+67%	+$6.5M	0.05%	516
2023 Q3	$9.63M	Buy	139,000 +114,200	+460%	+$9.18M	0.03%	635
2023 Q2	$2.34M	Sell	24,800 -36,900	-60%	-$3.21M	0.01%	1131
2023 Q1	$5.1M	Buy	61,700 +36,000	+140%	+$2.83M	0.02%	729
2022 Q4	$1.92M	Buy	25,700 +8,900	+53%	+$686K	0.01%	952
2022 Q3	$1.39M	Buy	16,800 +6,500	+63%	+$625K	0.01%	974
2022 Q2	$979K	Buy	+10,300	New	+$1.07M	0.01%	1078
2022 Q1	–	Sell	-44,900	Closed	-$5.82M	–	1540
2021 Q4	$5.82M	Buy	44,900 +7,900	+21%	+$921K	0.04%	578
2021 Q3	$4.19M	Buy	37,000 +24,000	+185%	+$2.74M	0.03%	647
2021 Q2	$1.35M	Buy	+13,000	New	+$1.23M	0.01%	1079
2021 Q1	–	Sell	-12,100	Closed	-$1.1M	–	1371
2020 Q4	$1.1M	Buy	12,100 +900	+8%	+$74.7K	0.01%	961
2020 Q3	$894K	Sell	11,200 -7,000	-38%	-$546K	0.01%	905
2020 Q2	$1.26M	Buy	18,200 +3,800	+26%	+$270K	0.02%	638
2020 Q1	$905K	Sell	14,400 -78,600	-85%	-$5.67M	0.01%	828
2019 Q4	$7.23M	Buy	93,000 +47,400	+104%	+$3.7M	0.06%	435
2019 Q3	$3.34M	Buy	45,600 +20,400	+81%	+$1.43M	0.03%	617
2019 Q2	$1.55M	Buy	25,200 +21,300	+546%	+$1.29M	0.01%	879
2019 Q1	$249K	Buy	+3,900	New	+$223K	﹤0.01%	1503
2018 Q3	–	Sell	-78,600	Closed	-$3.81M	–	2044
2018 Q2	$3.81M	Sell	78,600 -7,200	-8%	-$336K	0.02%	843
2018 Q1	$3.99M	Buy	+85,800	New	+$3.73M	0.02%	765
2017 Q3	–	Sell	-8,400	Closed	-$331K	–	1591
2017 Q2	$331K	Buy	+8,400	New	+$307K	﹤0.01%	1240
2017 Q1	–	Sell	-8,400	Closed	-$262K	–	1566
2016 Q4	$262K	Buy	8,400 +3,000	+56%	+$97.2K	﹤0.01%	1477
2016 Q3	$217K	Buy	+5,400	New	+$203K	﹤0.01%	1478
2015 Q3	–	Sell	-21,600	Closed	-$513K	–	1482
2015 Q2	$513K	Buy	21,600 +3,000	+16%	+$67.7K	0.01%	1066
2015 Q1	$442K	Buy	+18,600	New	+$417K	0.01%	1088
2014 Q1	–	Sell	-74,400	Closed	-$815K	–	1771
2013 Q4	$815K	Sell	74,400 -139,200	-65%	-$1.57M	0.01%	1062
2013 Q3	$2.48M	Buy	+213,600	New	+$2.5M	0.03%	569

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Fund Management (CFM)'s EW Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 16,061 shares — an estimated $1.32M sold.

Capital Fund Management (CFM) first reported a position in EW in Q1 2014 and held it in 34 quarters. The position peaked at $49M in Q4 2015. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Capital Fund Management (CFM) reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Capital Fund Management (CFM) sold 16,061 Edwards Lifesciences shares in Q1 2026, an estimated $1.32M.
Capital Fund Management (CFM) first reported a position in Edwards Lifesciences in Q1 2014 and held it in 34 quarters.
Capital Fund Management (CFM)'s Edwards Lifesciences position peaked at $49M in Q4 2015.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.